B 细胞淋巴瘤的 CAR20(NAP)-T 疗法(CARMA-01 研究) (CARMA-01)
评估 CAR20(NAP)-T 在复发/难治性 B 细胞淋巴瘤患者中的安全性和有效性的 I/IIa 期多中心研究(CARMA-01 研究)
The purpose is to study the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CAR20(NAP)-T for patients with B-cell malignancies.
研究概览
详细说明
A cancer patient's T cells can be isolated and engineered to express a chimeric antigen receptor (CAR), which re-directs the T cells to recognize and kill tumor cells expressing that particular antigen. CD19-targeted CAR-T cell therapy has shown good effects for B cell malignancies, even cure, in otherwise therapy refractory patients.
Antigen escape, i.e., the downregulation of the antigen targeted by the CAR due to the selective pressure caused by the CAR-T cell therapy is a challenge. For patients treated with CD19 CAR-T cell therapy, about 30% of the patients are resistant to treatment and about 20% of patients relapse after an initial response.
CAR20(NAP)-T cells target CD20 and upon target recognition secrete a bacterial-derived pluripotent immune-stimulating factor named NAP (Helicobacter pylori Neutrophil-activating protein). Secretion of NAP in the tumor microenvironment can induce an endogenous bystander immune response, that counteracts antigen escape and thereby improves the therapeutic outcome.
CAR20(NAP)-T is an investigational agent not yet approved by authorities.
Design:
The study is designed as 3+3 dose escalation phase I, and a dose expansion Phase IIa. The safety, tolerability, PK/PD, and efficacy will be evaluated.Dose escalation is to be based on the incidence of dose-limiting toxicity (DLTs). The investigator or sub-investigator will decide if the AE is related to IMP-treatment on a case-by-case basis depending on the character of the DLT symptoms. Investigator or sub-investigator has a possibility to classify various toxicity observed in patient as DLT.The Recommended phase II dose (RP2D) is decided based on safety, PK/PD data as well as preliminary clinical activity data from the Phase I dose escalation. After setting the RP2D, additional patients will be treated at RP2D to make sure at least 6 patients will be treated at RP2D dose level already at the phase I part.
Protocol treatment:
The enrolled patient will undergo a leukapheresis procedure to harvest enough T cells for IMP production. During CAR20(NAP)-T manufacturing, the patient may receive bridging therapy to control tumor burden. All patients will receive pre-conditioning chemotherapy (cyclophosphamide and fludarabine) followed by one dose of CAR20(NAP)-T cell infusion intravenously. The patient will then be followed by doctor/study nurse for evaluation of the health status and side effects. At follow-up visits, blood samples will be obtained and CT imaging will be performed. Patient will actively participate in the study for about 24 months when the final follow-up visit will be scheduled.
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Di Yu, PhD
- 电话号码:+46707204196
- 邮箱:di.yu@igp.uu.se
研究联系人备份
- 姓名:Gunilla Enblad, MD/PhD
- 电话号码:+46186110000
- 邮箱:gunilla.enblad@igp.uu.se
学习地点
-
-
-
Stockholm、瑞典
- 招聘中
- Karolinska University Hospital
-
接触:
- Stephan Mielke
-
首席研究员:
- Stephan Mielke, MD, PhD
-
Uppsala、瑞典
- 招聘中
- Uppsala University Hospital
-
接触:
- Gunilla Enblad
-
首席研究员:
- Gunilla Enblad, MD/PhD
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
-
Signed informed consent.
-
Relapsed or refractory CD20+ large B-cell lymphoma (DLBCL, NOS or high-grade malignant B-cell lymphoma), mantle cell lymphoma or indolent lymphoma.
-
The patient should have been treated with at least one line of therapy and have no curative treatment option, assessed by the Investigator and documented in the source data prior to enrolment, specifically:
- Relapsed or refractory CD20+ B-cell lymphoma that are not suitable to receive clinically approved CD19-directed CAR T cell treatment
- Relapsed or refractory CD20+ B-cell lymphoma who are considered CD19 neg-ative
- Relapsed or refractory B-cell lymphoma who relapse after CD19-directed CAR T cell treatment
- Not suitable for autologous stem cell transplant
- Relapsed after allogeneic transplantation
-
In phase I age >18 years, in phase II all ages.
-
Measurable disease per Lugano classification.
-
Performance status ECOG 0-2.
-
Bone marrow function, if impairment is not caused by lymphoma infiltration, as evidenced by:
- Absolute neutrophil count (ANC) ≥ 1x109/L
- Platelet ≥ 50x 109/L
- Absolute lymphocyte count ≥ 0.1x109/L
-
Adequate renal, hepatic, cardiac, and pulmonary function as evidenced by:
- Creatinine clearance (Cockcroft Gault) ≥ 30 mL/min
- Serum Alanine aminotransferase/Aspartate aminotransferase (ALT/AST) ≤ 2.5 Upper limit of normal (ULN) and S-Bilirubin <1.5x UNL
- Cardiac ejection fraction ≥ 40%
-
Functional venous access for administration of IMP.
-
Fertile individuals must consent to use contraceptives during participation in the trial.
Exclusion Criteria:
- Other CD20-positive lymphomas e.g Burkitt lymphoma, primary CNS lymphoma, plasmablastic lymphoma or CLL transformed to DLBCL/HGBL (Richter transformation)
- Any significant medical or psychiatric illness that would prevent the subject from giving informed consent or from following the study procedures.
- Known human immunodeficiency virus (HIV) infection.
- Impending organ-compromising disease.
- Rapidly progressing disease
- Active and/or severe infection (e.g., tuberculosis, sepsis and opportunistic infections, active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection.
- Other serious underlying medical conditions, which, in the Investigator's judgment, could impair the ability of the subject to tolerate the treatment.
- Treatment with an investigational product within 30 days prior to enrolment
- Potential sign of hypersensitivity reaction to tocilizumab or any of the agents used in this study
- Systemic corticosteroid treatment (>10mg/day) <5 days prior to IMP treatment or <7 days prior leukapheresis.
- Pregnancy
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Treatment
CAR20(NAP)-T treatment |
Autologous CAR-T cells targeting CD20 and upon target recognition express and secrete NAP
其他名称:
pre-conditioning chemotherapy pre-conditioning chemotherapy |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of dose limiting toxicity
大体时间:First infusion up to 30 days
|
The incidence of dose limiting toxicity (DLT). Number of Participants Experiencing Adverse Events (AEs) Defined as Dose Limiting Toxicities (DLTs) |
First infusion up to 30 days
|
|
Adverse events
大体时间:24 months
|
The nature, frequency, severity, and tolerability of adverse events (AEs) including clinically significant laboratory data, and their relation to dosage. |
24 months
|
|
Pharmacodynamic (PD) and pharmacokinetic (PK)
大体时间:Either 24 month or 15 years during long-term follow up if clinically indicated
|
PD is assessed by determine circulating B cell level; PK is assessed by determine circulating CAR20(NAP)-T cells. |
Either 24 month or 15 years during long-term follow up if clinically indicated
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Objective response rate [ORR]
大体时间:24 months
|
ORR is defined as the incidence of a complete response or a partial response by the revised Lugano classification as determined by the study investigators. All patients that do not meet the criteria for an objective response by the analysis cutoff date will be considered non-responders. |
24 months
|
|
Progression free survival [PFS]
大体时间:24 months
|
PFS is defined as the time from the IMP treatment date to the date of disease progression per the revised Lugano classification or death from any cause. |
24 months
|
|
Best Objective Response
大体时间:24 months
|
the incidence of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or unevaluable (UE) as best response to treatment. |
24 months
|
|
Duration of Response (DOR)
大体时间:24 months
|
DOR is defined as the date of their first objective response (which is subsequently confirmed) to disease progression per the revised Lugano classification or death regardless of cause. Patients not meeting the criteria for progression or death by the analysis data cutoff date will be censored at their last evaluable disease assessment date and their response will be noted as ongoing. |
24 months
|
|
Overall Survival (OS)
大体时间:either 24 months or 15 years during long-term follow up if clinically indicated
|
defined as the time from IMP treatment to the date of death. Patients alive by the analysis data cutoff date will be censored at their last contact date. The overall survival rate will be reported at different cut-off time points. |
either 24 months or 15 years during long-term follow up if clinically indicated
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Anti-NAP response
大体时间:either 24 months or 15 years during long-term follow up if clinically indicated
|
Determine anti-NAP immune response |
either 24 months or 15 years during long-term follow up if clinically indicated
|
|
Bystander immunity activation
大体时间:either 24 months or 15 years during long-term follow up if clinically indicated
|
Assess induced tumor specific endogenous T-cell immune response |
either 24 months or 15 years during long-term follow up if clinically indicated
|
合作者和调查者
调查人员
- 研究主任:Di Yu, PhD、Uppsala University
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- ELC301-CARMA-01
- 2022-004157-31 (EudraCT编号)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.